inc la jolla ca base
biopharma compani oper lean busi
model invest royalti asset technolog
excipi use pharma product run small
reason report
price chang estim chang analysi
intact desir exposur omniab anticip
fundament believ compani specif pushback
signific enough compound drag distract
materi promacta competit mani taker flip side
mileston comp appreci sinc
adjust estim mil revenu
estim mil revenue adj
ep compar previou expect mil
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
result encourag suggest promacta momentum continu link previou note
weekli higher dose kyproli use combin dexamethason treatment patient relapsed/
fda psychopharmacolog drug advisori committe drug safeti risk manag advisori
acquir structure-bas drug discoveri biotech compani vernali mil cash off-set
given paid mil convert note immedi post quarter estim compani
compani mil share repurchas author said evalu whether recent
except per share data
good sold
amort intang
decrease/ increas conting liabil
 loss vike
net loss attribut nci
net incom attribut
forma ep exclud non-recur expens period neg ep basic share outstand use
compani report stephen inc estim
thousand except share data
clinic materi sale
commerci materi sale
licens fee revenu
percent sale analysi
royalti revenu recogn one-quart lag prior exampl royalti revenu base partner drug sale
compani report stephen inc estim
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
